Lawtons Drugs

lawtons.ca

As a parent company and a strong supporter of Lawtons Drugs, Sobeys core values reflect the commitment and convictions that have helped shape the company over the past 100 years. Since our 1907 beginning as a small pharmacy in Newfoundland, Lawtons Drugs has portrayed integrity, commitment to its employees, and a desire to consistently exceed customer expectations in service, value and product selection. Lawtons Drugs has since grown to 80 locations in Atlantic Canada with plans to expand even further. Our pharmacy services complement customers’ prescriptions and help them manage their family’s medication and health care needs. Lawtons Drugs has a full line of home healthcare solutions, beauty, cosmetics, convenience and giftware products to suit everyone’s needs.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

VENENO TECHNOLOGIES, A NOVEL DRP DRUG DISCOVERY COMPANY, RAISES $2MILLION (¥200M YEN) IN SEED FUNDING ROUND

Veneno Technologies Co. Ltd. | January 27, 2022

news image

Veneno Technologies Co. Ltd. is pleased to announce that it has completed fundraising of 200 million yen through a third-party allocation of new shares to SBI Investment Co., Ltd., Tsukuba Institute of Research, Ltd., and SBI regional activation support Co., Ltd. The funds raised will be used to strengthen the recruitment and organizational structure, to further develop the Company's proprietary peptide drug discovery platform technology, and invest in the research and develop...

Read More

PHARMA TECH

AMERISOURCEBERGEN PARTNERS WITH CHRONICLED TO OPTIMIZE PHARMACEUTICAL CHARGEBACK ACCURACY USING BLOCKCHAIN-POWERED TECHNOLOGY

AmerisourceBergen | April 22, 2022

news image

Global healthcare company AmerisourceBergen announced its partnership with Chronicled, the administrator of the MediLedger Network, to leverage a new blockchain-powered solution designed to enhance pharmaceutical chargeback accuracy and significantly reduce chargeback rejections. The blockchain solution will allow AB to streamline and optimize the complex process of pharmaceutical chargebacks while creating greater connectivity for its suppliers and customers. Over the past three years, AB has c...

Read More

PHARMACY MARKET

JUBILANT HOLLISTERSTIER LLC ENTERS INTO COOPERATIVE AGREEMENT OF $149.6 MN WITH US GOVERNMENT TO EXPAND CRITICAL VACCINE MANUFACTURING CAPACITY

Jubilant Pharmova Limited | May 31, 2022

news image

Jubilant Pharmova Limited has announced today that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based pharmaceutical contract manufacturer has entered into a cooperative agreement for $149.6 million (USD) with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of th...

Read More

PHARMACY MARKET

VIPERGEN AND LEO PHARMA PARTNER FOR DNA ENCODED LIBRARY (DEL)-BASED DRUG DISCOVERY FOR DERMATOLOGY INDICATIONS

Vipergen | June 20, 2022

news image

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma t...

Read More
news image

PHARMACY MARKET

VENENO TECHNOLOGIES, A NOVEL DRP DRUG DISCOVERY COMPANY, RAISES $2MILLION (¥200M YEN) IN SEED FUNDING ROUND

Veneno Technologies Co. Ltd. | January 27, 2022

Veneno Technologies Co. Ltd. is pleased to announce that it has completed fundraising of 200 million yen through a third-party allocation of new shares to SBI Investment Co., Ltd., Tsukuba Institute of Research, Ltd., and SBI regional activation support Co., Ltd. The funds raised will be used to strengthen the recruitment and organizational structure, to further develop the Company's proprietary peptide drug discovery platform technology, and invest in the research and develop...

Read More
news image

PHARMA TECH

AMERISOURCEBERGEN PARTNERS WITH CHRONICLED TO OPTIMIZE PHARMACEUTICAL CHARGEBACK ACCURACY USING BLOCKCHAIN-POWERED TECHNOLOGY

AmerisourceBergen | April 22, 2022

Global healthcare company AmerisourceBergen announced its partnership with Chronicled, the administrator of the MediLedger Network, to leverage a new blockchain-powered solution designed to enhance pharmaceutical chargeback accuracy and significantly reduce chargeback rejections. The blockchain solution will allow AB to streamline and optimize the complex process of pharmaceutical chargebacks while creating greater connectivity for its suppliers and customers. Over the past three years, AB has c...

Read More
news image

PHARMACY MARKET

JUBILANT HOLLISTERSTIER LLC ENTERS INTO COOPERATIVE AGREEMENT OF $149.6 MN WITH US GOVERNMENT TO EXPAND CRITICAL VACCINE MANUFACTURING CAPACITY

Jubilant Pharmova Limited | May 31, 2022

Jubilant Pharmova Limited has announced today that Jubilant Pharma Limited, a wholly owned subsidiary of the Company, through one of its wholly owned subsidiaries, Jubilant HollisterStier LLC, (JHS) a leading US-based pharmaceutical contract manufacturer has entered into a cooperative agreement for $149.6 million (USD) with the Army Contracting Command, in coordination with the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense (JPEO-CBRND) on behalf of th...

Read More
news image

PHARMACY MARKET

VIPERGEN AND LEO PHARMA PARTNER FOR DNA ENCODED LIBRARY (DEL)-BASED DRUG DISCOVERY FOR DERMATOLOGY INDICATIONS

Vipergen | June 20, 2022

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma t...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us